Haematologica
HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Weisser, M
Right arrow Articles by Kolb, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Weisser, M
Right arrow Articles by Kolb, H.
Haematologica, Vol 91, Issue 5, 663-666
Copyright © 2006 by Ferrata Storti Foundation

Comparative Study

A comparison of donor lymphocyte infusions or imatinib mesylate for patients with chronic myelogenous leukemia who have relapsed after allogeneic stem cell transplantation

M Weisser, J Tischer, S Schnittger, C Schoch, G Ledderose, and HJ Kolb

Department of Internal Medicine III, University of Munich, Klinikum Grosshadern, Munich, Germany. martin.weisser@med.unimuenchen.de

Imatinib mesylate is highly effective in relapsed chronic myelogenous leukemia (CML) after allogeneic hematopoetic stem cell transplantation (HSCT). However, it is unknown whether imatinib produces durable molecular remissions. The outcome of CML patients transplanted at our center who had received only imatinib for relapse after HSCT was compared with that of patients treated with donor lymphocyte infusions (DLI). Imatinib therapy resulted in a higher incidence of relapse and inferior leukemia-free survival (p=0.006 and p=0.016, respectively). These data suggest that imatinib alone probably does not cure relapse after HSCT.


This article has been cited by other articles:


Home page
 BloodHome page
J. M. Goldman
How I treat chronic myeloid leukemia in the imatinib era
Blood, October 15, 2007; 110(8): 2828 - 2837.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. Dominietto, S. Pozzi, M. Miglino, F. Albarracin, G. Piaggio, F. Bertolotti, R. Grasso, S. Zupo, A. M. Raiola, M. Gobbi, et al.
Donor lymphocyte infusions for the treatment of minimal residual disease in acute leukemia
Blood, June 1, 2007; 109(11): 5063 - 5064.
[Full Text] [PDF]

Home page
 ASH Education BookHome page
S. Branford
Chronic Myeloid Leukemia: Molecular Monitoring in Clinical Practice
Hematology, January 1, 2007; 2007(1): 376 - 383.
[Abstract] [Full Text] [PDF]

Home page
 ASH Education BookHome page
J. F. Apperley
Managing the Patient with Chronic Myeloid Leukemia Through and After Allogeneic Stem Cell Transplantation
Hematology, January 1, 2006; 2006(1): 226 - 232.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
Copyright © 2006 by the Ferrata Storti Foundation.